

**REPLY: Diet-Induced Obesity HFpEF  
Murine Models**

We thank Dr. Carbone and colleagues for their suggestion to add the diet-induced model of obesity to our recent review of murine models of heart failure with preserved ejection fraction (HFpEF) (1). The diet-induced obesity model (including high-fat diets, Western diet, and others) is an important model in the context of cardiac remodeling and cardiac dysfunction. It is known that mice and rats that are fed these types of diets become obese; frequently, but not always, develop a cardiac phenotype characterized by cardiac hypertrophy, fibrosis, and diastolic dysfunction (2-6); and may also develop systolic dysfunction with a depressed left ventricular ejection fraction (7). These features depend on several parameters, such as study duration, caloric intake, and, as mentioned by the authors, the specific composition of nutrients in the diet (% saturated and unsaturated fat, as well as carbohydrates). Carbone and colleagues, as well as others, showed that obese mice fed a Western or high-fat diet had higher left ventricular end-diastolic pressure by invasive hemodynamics than nonobese mice on a control diet (6,8). It has also been shown that Western diet-induced obesity caused impairment in exercise capacity (9). Conversely, others have found no cardiac phenotype with a high-fat diet (10). We, therefore, agree with the authors that with some *select* diets, the diet-induced obesity model *may be* representative of HFpEF. However, not all diet-induced obesity models mirror HFpEF in humans (9,10). Finally, to our knowledge, we are unaware of any other studies of diet-induced obesity, in either mice or rats, where post-mortem pulmonary congestion was assessed.

We would also like to again re-emphasize that diastolic dysfunction is not a surrogate for HFpEF in preclinical studies, nor is it enough to establish it, as diastolic dysfunction occurs in *heart failure with reduced ejection fraction* (HFrEF) (1).

Recently, the quest for the perfect animal model to phenocopy human HFpEF has overtaken the heart failure field (11). This is likely because of alarm over why clinical trials in HFpEF have been negative/neutral, and this concern has extended to scrutinizing preclinical studies. This intense dissection did not occur in animal models of HFrEF where, for example, left anterior descending artery ligation was simply a model of ischemic

cardiomyopathy/HFrEF due to coronary artery disease. There was no cause for concern that these animal models did not include hypertension, obesity, type 2 diabetes mellitus, or tobacco exposure, despite these being very strong risk factors for coronary artery disease. That being said, both clinical and experimental HFpEF are dissimilar to HFrEF, and the challenges that are outlined in the review persist (1). Murine models of HFpEF that represent HFpEF in humans are important tools to study HFpEF, as they provide mechanistic insights into this challenging disease/syndrome (12-15).

**Maria Valero-Muñoz, PhD**

**\*Flora Sam, MD**

\*Whitaker Cardiovascular Institute  
Cardiovascular Medicine Section  
Boston University School of Medicine  
700 Albany Street, W507  
Boston, Massachusetts 02118

E-mail: [flora.sam@bmc.org](mailto:flora.sam@bmc.org)

<https://doi.org/10.1016/j.jaccbts.2018.01.006>

© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Please note: Dr. Valero-Muñoz was supported by a grant from American Heart Association (17POST33660439). Dr. Sam was supported by a grant from the National Institutes of Health (HL117153).

All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Basic to Translational Science* author instructions page.

**REFERENCES**

1. Valero-Muñoz M, Backman W, Sam F. Murine models of heart failure with preserved ejection fraction: a "fishing expedition." *J Am Coll Cardiol Basic Trans Science* 2017;2:770-89.
2. Huang JP, Cheng ML, Wang CH, Shiao MS, Chen JK, Hung LM. High-fructose and high-fat feeding correspondingly lead to the development of lysoPC-associated apoptotic cardiomyopathy and adrenergic signaling-related cardiac hypertrophy. *Int J Cardiol* 2016;215:65-76.
3. Leopoldo AS, Sugizaki MM, Lima-Leopoldo AP, et al. Cardiac remodeling in a rat model of diet-induced obesity. *Can J Cardiol* 2010;26:423-9.
4. Christopher BA, Huang HM, Berthiaume JM, et al. Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. *Am J Physiol Heart Circ Physiol* 2010;299:H1917-27.
5. Manrique C, DeMarco VG, Aroor AR, et al. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. *Endocrinology* 2013;154:3632-42.
6. Carbone S, Mauro AG, Mezzaroma E, et al. A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice. *Int J Cardiol* 2015;198:66-9.
7. Cheng Y, Li W, McElfresh TA, et al. Changes in myofibrillar proteins, but not Ca(2+)-regulation, are associated with a high-fat diet-induced improvement in contractile function in heart failure. *Am J Physiol Heart Circ Physiol* 2011;301:H1438-46.

- 8.** Patel VB, Mori J, McLean BA, et al. ACE2 Deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. *Diabetes* 2016;65:85-95.
- 9.** Chiang SH, Harrington WW, Luo G, et al. Genetic ablation of CD38 protects against western diet-induced exercise intolerance and metabolic inflexibility. *PLoS One* 2015;10:e0134927.
- 10.** Brainard RE, Watson LJ, Demartino AM, et al. High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. *PLoS One* 2013;8:e83174.
- 11.** Roh J, Houstis N, Rosenzweig A. Why don't we have proven treatments for HFpEF? *Circ Res* 2017;120:1243-5.
- 12.** Lai YC, Tabima DM, Dube JJ, et al. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. *Circulation* 2016;133:717-31.
- 13.** Tanaka K, Valero-Munoz M, Wilson RM, et al. Follistatin like 1 regulates hypertrophy in heart failure with preserved ejection fraction. *J Am Coll Cardiol Basic Trans Science* 2016;1:207-21.
- 14.** Valero-Munoz M, Li S, Wilson RM, Boldbaatar B, Iglarz M, Sam F. Dual endothelin-A/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction. *Circ Heart Fail* 2016;9:e003381.
- 15.** Gevaert AB, Shakeri H, Leloup AJ, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. *Circ Heart Fail* 2017;10:e003806.